openPR Logo
Press release

Cancer Immunotherapy Market Worth $152.83 Billion By 2024| Key players are F. Hoffmann-La Roche , Celgene, Bristol-Myers Squibb, Merck & Co., Inc., Amgen Inc. , ELI Lilly , Janssen Global Services,, Novartis , Gilead Sciences, Inc., Dendreon Pharmaceutica

07-12-2019 10:37 AM CET | Health & Medicine

Press release from: Meticulous Research®

Cancer Immunotherapy Market Worth $152.83 Billion By 2024

Cancer Immunotherapy Market Worth $152.83 Billion By 2024

The global cancer immunotherapy market study presents historical market data in terms of values (2016 and 2017), estimated current data (2018), and forecasts for 2024-by product (monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy), application (lung cancer, breast cancer, multiple myeloma, colorectal cancer, melanoma, prostate cancer, and other cancer types), and end user (hospitals, and clinics & others). The study also evaluates industry competitors and analyzes the market at regional and country level.

On the basis of product type, monoclonal antibodies segment commanded the largest share of the global cancer immunotherapy market in 2017. However, checkpoint inhibitors market is expected to grow at the fastest CAGR during the forecast period, owing to high success rate of PD-1 & PD-L1 drugs and increasing pipelines of biotechnology and pharmaceutical companies with combination therapies for anti-PD-1 and PD-L1 inhibitors. Moreover, cell therapy market is also expected to witness significant growth through 2024. Development of new and effective therapy options to cure symptoms of the disease is a key factor contributing to growth of cell therapy market.

Browse in-depth Report on -

On the basis of application, cancer immunotherapy market for lung cancer application commanded the largest share of the global market in 2017. Major factors propelling the growth of cancer immunotherapy market in lung cancer application are growing incidence, mortality rate, and benefits of immunotherapy to the lung cancer patients; whereas, cancer immunotherapy market for multiple myeloma applications expected to witness the highest growth rate during the forecast period. The approval of innovative caner immunotherapy for the treatment of multiple myeloma has increased the adoption of immunotherapies in treatment of multiple myeloma. Moreover, recognizing the potential of immunotherapy in multiple myeloma, major players in immunotherapy market such as Celgene, Amgen, Janssen, and Juno Therapeutics engaged in multiple collaborations to evaluate certain drug entities for the treatment of multiple myeloma.

On the basis of end user, hospitals dominated the global market. This is mainly attributed to the rise in healthcare spending which has resulted in the increasing use of immunotherapeutic drugs in hospitals and the large number of patients being treated in hospitals for cancer immunotherapy; however, clinics and other end user markets are expected to witness a rapid growth during the forecast period with the increasing number of clinics providing cancer immunotherapy, and rising number of ongoing clinical trials for immunotherapy drugs.

Request for a sample of this research report @ -

This research report analyzes major geographies and provides comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America, and Middle East & Africa. North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and Asia Pacific. However, Asia Pacific region is expected to grow at a higher CAGR during the forecast period. Growth in this market is expected to be driven by large pool of patient population seeking the cancer treatment, increasing prevalence of cancer, aggressive investment by the major players in the market, increasing government spending on the healthcare, and increasing disposable income of the population that improved the access to cancer treatment. Furthermore, lack of stringent regulations and liberalization in Asian countries is also a key factor making Asia Pacific a lucrative market.

Key topics covered in Report:

1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation

3. Executive Summary
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis

4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer incidence
4.2.2. Growing Adoption of Immunotherapy Over Other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to initiate the Clinical Trials
4.5.2. Complexities of Tumor

5. Industry insights
5.1. Key industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China’s Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. OPDIVO and Keytruda: Major Products in Cancer Immunotherapy Market

6. Cancer Immunotherapy Market, by Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies

7. Cancer Immunotherapy Market, by Application
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types

8. Cancer Immunotherapy Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others

9. Cancer Immunotherapy Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa

10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments

11. Company Profiles (Overview, Products and Services, Financials, and Developments)
11.1. AstraZeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis Ag
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene Corporation

12. Appendix
12.1. Questionnaire
12.2. Available Customization

Enquire Before Buying:

The major players operating in the global cancer immunotherapy market are F. Hoffmann-La Roche (Switzerland), Celgene Corporation (US), Bristol-Myers Squibb (US), Merck & Co., Inc. (US), and Amgen Inc. (US),ELI Lilly and Company (US), Janssen Global Services, LLC (US) (Johnson and Johnson), Novartis (Switzerland), Pfizer, Inc. (US), Gilead Sciences, Inc. (US), Dendreon Pharmaceuticals (US), and Bayer (Germany) among others.

Contact Info:
Contact Sales- +91-744-7780008

Office No-202, 203,204,205,206;
2nd Floor, Pushpak Business Hub,
Wakad, Pimpri-Chinchwad,
411057, India.

For Sales Enquires
India: +91-744-7780008
U.S.: +1-646-781-8004

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cancer Immunotherapy Market Worth $152.83 Billion By 2024| Key players are F. Hoffmann-La Roche , Celgene, Bristol-Myers Squibb, Merck & Co., Inc., Amgen Inc. , ELI Lilly , Janssen Global Services,, Novartis , Gilead Sciences, Inc., Dendreon Pharmaceutica here

News-ID: 1802762 • Views: 116

More Releases from Meticulous Research®

Radiotherapy Market Worth $10.15 billion by 2025 at a CAGR of 5.6% from 2019 to …
Meticulous Research® – leading global market research company published a research report titled “Radiotherapy Market by Product (Radiotherapy devices, Software, Service), By Procedure (EBRT, Brachytherapy, Systemic Radiotherapy), By Technology (IMRT, SRT, VMAT, HDRBT, LDRBT, PDRBT), By Application (Prostate, Breast) – Global Forecasts to 2025”. Download a Free Sample Report Now @ According to this latest publication from Meticulous Research®, the global radiotherapy market is expected to grow at a CAGR
The Future Of Telehealth | Telemedicine Market : What Covid19 impact does this h …
Meticulous Research® –leading global market research company published a research report titled “Telehealth market/Telemedicine Market by Component (Service, Software, Device), Mode of Delivery (On premise, Web, Cloud), Application (Radiology, Cardiology, Primary/Urgent Care, ICU, Mental Health), End User (Physician, Payor, Patient) — Global Forecast to 2023”. According to this latest publication from Meticulous Research®, the global telehealth market is expected to grow at a CAGR of 23.0% from 2018 to 2023 to
Smart Cities Market Analysis, Post Covid-19 Impact | Potential Business Impacts …
Meticulous Research® — a leading global market research company published a research report titled “Smart Cities Market by Application (Smart Utilities, Smart Transportation, Water Management, Waste Management, Smart Healthcare, Smart Lighting, Smart Education), Component (Hardware, Software, and Services), and Geography- Global Forecast to 2027”. According to this latest publication from Meticulous Research®, the Smart Cities Market is expected to grow at a CAGR of 22.9% from 2019 to reach $545.7 billion
Pre & Post COVID-19 Market Estimates- Ventilators Market Worth $7.72 billion by …
According to a new market research report “Ventilators Market by Product (Instruments, Accessories), Mobility (Intensive Care, Portable), Interface (Invasive, Non-invasive), Age Group (Adult, Pediatric), Mode (Volume, Pressure, Dual), End User (Hospital, ASCs, Home Care) — Global Forecast to 2027”, published by Meticulous Research, the ventilators market is expected to grow at a CAGR of 15.8% from 2020 to reach $7.72 billion by 2027. Download Free Sample Report Now @ Ventilatory intervention

All 5 Releases

More Releases for Cancer

Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and